RxDoctor Payments Data

Sajan Nagpal, MD

Gastroenterology · Eagan, MNNPI 1073950911

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $41,213 of the $45,877 with a category attached, or 89.8%. 3 manufacturers reported payments, led by Aimmune Therapeutics, Inc. at 55.3% of the total. 2025 is the largest year on record at $25,071, 3.6 times the $7,000 reported in 2021. Among gastroenterology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,877in general payments, 2019–2025

Across 33 payments — averaging $1390.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$25K
  • Nestle Healthcare Nutrition Inc.$14K
  • AbbVie$6K

What the payments were for

  • Consulting fees$2,8006%
  • Speaking & faculty fees$41,21390%
  • Travel & lodging$1,5833%
  • Food & beverage$2821%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Aimmune Therapeutics, Inc.19$25,384
Nestle Healthcare Nutrition Inc.11$14,193
AbbVie3$6,300

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,877 in reported general payments places this provider in the 90th percentile of 365 gastroenterology providers in Minnesota.

See all gastroenterology providers in Minnesota

Medicare billing

Part B allowed, 2024
$129,928
Medicare patients
225
Services billed
4,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase27$65,057
LinzessLinaclotide16$12,999
Colestipol Hcl21$2,512
Omeprazole99$1,806
Ondansetron OdtOndansetron15$484
Dicyclomine Hcl14$229
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl11$201
Famotidine12$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$6,300$78,05643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 gastroenterology providers in Minnesota.

Other gastroenterology in Eagan

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →